Compumedics (ASX:CMP) granted U.S. FDA for Neuroimaging technology
- Compumedics (CMP) has received clearance from the U.S. Food and Drug Administration (FDA) for its neuroimaging technology
- The clearance allows for routine clinical use of the MEG devices, mainly for epilepsy and pre-surgical brain function mapping
- Sites using the technology can now routinely bill private and public insurance plans for the examination
Granted U.S. FDA for Neuroimaging technology
Add CMP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $46.06M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.0¢ | 26.0¢ | $2.984K | 11.47K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2724 | 26.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 13.55pm 06/05/2024 (20 minute delay) ? |
| CMP (ASX) Chart |